Latest Breaking News On - Aptamer radioligand conjugate - Page 1 : comparemela.com

/PRNewswire/ Aptamer Sciences Inc. (KOSDAQ, 291650) announced the filing of an Investigational New Drug (IND) application for the phase 1 clinical trial of.

Kyonggi doSouth koreaHong jae chonAprc aptamer radioligandNational cancer centerAptamer sciences incBundang medical centerSamsung medical centerKorean ministry of foodAptamer sciencesInvestigational new drugKorean ministryDrug safetyAptamer drug conjugateEast asiaNature medicine